Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies.
Carneiro BA, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma WW, Coveler AL, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weisskittel T, Li H, Borden BA, Harvey RD, Sahebjam S, Cervantes A, Koukol A, Mazar AP, Steeghs N, Kurzrock R, Giles FJ, Munster P.
Carneiro BA, et al. Among authors: mahalingam d.
Clin Cancer Res. 2024 Feb 1;30(3):522-531. doi: 10.1158/1078-0432.CCR-23-1916.
Clin Cancer Res. 2024.
PMID: 37982822
Clinical Trial.